Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
|
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [21] Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors
    Li, Junhua
    Hu, Qingqing
    Zhu, Run
    Dong, Ruibo
    Shen, Hui
    Hu, Jiankang
    Zhang, Cheng
    Zhang, Xiaohan
    Xu, Tingting
    Xiang, Qiuping
    Zhang, Yan
    Lin, Bin
    Zhao, Linxiang
    Wu, Xishan
    Xu, Yong
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (23) : 21577 - 21616
  • [22] Molecular dynamics insights into binding selectivity of inhibitors toward BRD4 and CBP
    Wu, Shiliang
    Wang, Lifei
    Zhang, Lulu
    Xu, Xiaoyan
    Zhao, Juan
    CHEMICAL PHYSICS LETTERS, 2021, 769
  • [23] Discovery of a potent, orally available tricyclic derivative as a novel BRD4 inhibitor for melanoma
    Horai, Yuhei
    Suda, Naoki
    Uchihashi, Shinsuke
    Katakuse, Mayako
    Shigeno, Tomomi
    Hirano, Takashige
    Takahara, Junichi
    Fujita, Tomoyuki
    Mukoyama, Yohei
    Haga, Yuji
    BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 93
  • [24] Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design
    Duffy, Bryan C.
    Liu, Shuang
    Martin, Gregory S.
    Wang, Ruifang
    Hsia, Ming Min
    Zhao, He
    Guo, Cheng
    Ellis, Michael
    Quinn, John F.
    Kharenko, Olesya A.
    Norek, Karen
    Gesner, Emily M.
    Young, Peter R.
    McLure, Kevin G.
    Wagner, Gregory S.
    Lakshminarasimhan, Damodharan
    White, Andre
    Suto, Robert K.
    Hansen, Henrik C.
    Kitchen, Douglas B.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (14) : 2818 - 2823
  • [25] Charting the Bromodomain BRD4: Towards the Identification of Novel Inhibitors with Molecular Similarity and Receptor Mapping
    Prieto-Martinez, Fernando D.
    Medina-Franco, Jose L.
    LETTERS IN DRUG DESIGN & DISCOVERY, 2018, 15 (09) : 1002 - 1011
  • [26] Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
    Liang, Dailin
    Yu, Yifan
    Ma, Zonghui
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 200
  • [27] BRD4 promotes gouty arthritis through MDM2-mediated PPARγ degradation and pyroptosis
    Xu, Xiaoxia
    Qiu, Hongbin
    MOLECULAR MEDICINE, 2024, 30 (01)
  • [28] Transcriptional regulation of interferon stimulated genes: Role of chromatin binding protein Brd4
    Patel, Mira
    Debrosse, Maxime
    Smith, Matthew
    Dev, Anup
    WalterHuynh
    Tamura, Tomohiko
    Heightman, Tom
    Ozato, Keiko
    CYTOKINE, 2010, 52 (1-2) : 16 - 16
  • [29] Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
    Zhang, Fangqing
    Wu, Zhenwei
    Chen, Pan
    Zhang, Jian
    Wang, Tao
    Zhou, Jinpei
    Zhang, Huibin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (01)
  • [30] Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails
    Liu, Ying
    Wang, Xiqing
    Zhang, Jiahai
    Huang, Hongda
    Ding, Bo
    Wu, Jihui
    Shi, Yunyu
    BIOCHEMISTRY, 2008, 47 (24) : 6403 - 6417